Key result
Newer antiplatelet therapies targeting novel platelet pathways are being developed to overcome the safety, efficacy, and tolerability limitations of aspirin.
Population
Patients requiring antiplatelet therapy for conditions such as myocardial infarction, ischemia, and stroke
Comparison
Newer antiplatelet therapies targeting enzymes… vs Aspirin and currently used antiplatelet inhibitors
Design
Review
Authors
Loading...
Current antiplatelet limitations persist in practice; review extends target identification but leaves clinical translation open.
This review summarizes the limitations of current antiplatelet therapies and outlines the development of newer agents targeting novel platelet pathways to improve safety and efficacy.
Holinstat et al. (2012) conducted a review in Myocardial infarction, ischemia, and stroke. Newer antiplatelet therapies vs. Aspirin was evaluated. Newer antiplatelet therapies targeting novel platelet pathways are being developed to overcome the safety, efficacy, and tolerability limitations of aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: